Luis Francisco Lorenzo Martín-rekin lankidetzan egindako argitalpenak (10)

2022

  1. A hotspot mutation targeting the R-RAS2 GTPase acts as a potent oncogenic driver in a wide spectrum of tumors

    Cell Reports, Vol. 38, Núm. 11

  2. Characterization of the spectrum of trivalent VAV1-mutation-driven tumours using a gene-edited mouse model

    Molecular Oncology, Vol. 16, Núm. 19, pp. 3533-3553

2021

  1. Cancer-associated mutations in VAV1 trigger variegated signaling outputs and T-cell lymphomagenesis

    EMBO Journal, Vol. 40, Núm. 22

2020

  1. Computational and in vitro Pharmacodynamics Characterization of 1A-116 Rac1 Inhibitor: Relevance of Trp56 in Its Biological Activity

    Frontiers in Cell and Developmental Biology, Vol. 8

  2. Rho guanosine nucleotide exchange factors are not such bad guys after all in cancera

    Small GTPases, Vol. 11, Núm. 4, pp. 233-239

  3. VAV2 signaling promotes regenerative proliferation in both cutaneous and head and neck squamous cell carcinoma

    Nature Communications, Vol. 11, Núm. 1

  4. Vav2 pharmaco-mimetic mice reveal the therapeutic value and caveats of the catalytic inactivation of a Rho exchange factor

    Oncogene, Vol. 39, Núm. 28, pp. 5098-5111

2019

  1. Vav proteins maintain epithelial traits in breast cancer cells using miR-200c-dependent and independent mechanisms

    Oncogene, Vol. 38, Núm. 2, pp. 209-227

2018

  1. An unexpected tumor suppressor role for VAV1a

    Molecular and Cellular Oncology, Vol. 5, Núm. 3

2017

  1. A Paradoxical Tumor-Suppressor Role for the Rac1 Exchange Factor Vav1 in T Cell Acute Lymphoblastic Leukemia

    Cancer Cell, Vol. 32, Núm. 5, pp. 608-623.e9